Last 47 quarters of trend data · Healthcare · Metabolic & Cardiovascular Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1416.44 | — | — | 524.43 | — | — | 294.23 | 191.15 | — | 699.55 | 7245.67 | 4247.30 | — | 7643.55 | — | 3295.92 | 31.77 | — | — | — | 245.27 |
| — | — | — | +174.4% | — | — | -95.9% | -95.5% | — | -90.8% | — | +28.9% | — | — | — | — | -87.0% | — | — | — | — | |
| P/B Ratio | 1.57 | 8.43 | 4.33 | 2.92 | 1.88 | 2.22 | 2.22 | 1.48 | 1.89 | 2.97 | 6.04 | 2.69 | 2.28 | 5.65 | 5.12 | 3.76 | 11.52 | 6.64 | 2.85 | 4.03 | 5.68 |
| — | +279.5% | +94.5% | +97.2% | -0.8% | -25.2% | -63.2% | -45.0% | -16.8% | -47.5% | +18.1% | -28.4% | -80.2% | -14.9% | +79.2% | -6.7% | +102.7% | +3.5% | -60.8% | -6.9% | +53.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -27160.0% | — | — | -11933.3% | — | — | -17250.0% | 100.0% | — | -4400.0% | -100.0% | -93200.0% | — | -129550.0% | — | -28145.5% | 76.3% | — | — | — | 100.0% |
| — | — | — | -12033.3% | — | — | -17150.0% | +100.1% | — | +96.6% | — | -231.1% | — | — | — | — | -23.7% | — | — | — | — | |
| Operating Margin | -84500.0% | — | — | -30233.3% | — | — | -54600.0% | -18875.0% | — | -29150.0% | -174200.0% | -794900.0% | — | -199550.0% | — | -77463.6% | -283.9% | — | — | — | -5602.0% |
| — | — | — | -60.2% | — | — | +68.7% | +97.6% | — | +85.4% | — | -926.2% | — | — | — | — | +94.9% | — | — | — | — | |
| Net Margin | -83520.0% | — | — | -29766.7% | — | — | -53650.0% | -18550.0% | — | -28225.0% | -168200.0% | -784300.0% | — | -219325.0% | — | -83263.6% | -304.1% | — | — | — | -5711.8% |
| — | — | — | -60.5% | — | — | +68.1% | +97.6% | — | +87.1% | — | -841.9% | — | — | — | — | +94.7% | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -198.1% | -98.1% | -58.5% | -36.0% | -35.9% | -44.5% | -68.8% | -31.0% | -34.7% | -26.4% | -30.3% | -77.6% | -47.7% | -34.3% | -29.5% | -25.9% | -24.5% | -22.2% | -18.3% | -18.6% | -29.0% |
| — | -120.3% | +15.0% | -16.2% | -3.3% | -69.0% | -127.0% | +60.1% | +27.2% | +23.2% | -2.6% | -199.5% | -94.7% | -54.2% | -61.7% | -39.3% | +15.5% | +4.9% | +2.7% | -9.9% | -119.8% | |
| ROA | -146.0% | -56.0% | -41.5% | -26.7% | -27.4% | -30.7% | -44.0% | -23.5% | -27.4% | -21.1% | -23.5% | -56.6% | -35.8% | -22.9% | -17.7% | -13.8% | -12.5% | -12.5% | -10.9% | -11.3% | -20.6% |
| — | -82.7% | +5.7% | -13.4% | -0.0% | -45.5% | -87.1% | +58.4% | +23.5% | +8.0% | -33.0% | -308.9% | -185.6% | -83.3% | -62.6% | -22.5% | +39.2% | +35.2% | +30.6% | +22.5% | -76.4% | |
| ROIC | -364.2% | -97.7% | -89.2% | -83.3% | -108.1% | -102.5% | -95.7% | -56.3% | -73.4% | -89.2% | -291.3% | -353.6% | -135.2% | -47.7% | -36.5% | -32.0% | -43.3% | -73.2% | -59.0% | -78.7% | -136.4% |
| — | +4.7% | +6.8% | -48.1% | -47.2% | -14.8% | +67.1% | +84.1% | +45.7% | -87.0% | -698.2% | -1005.4% | -212.1% | +34.8% | +38.2% | +59.4% | +68.2% | +41.0% | +56.3% | +40.8% | -6.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | 0.08 | 0.07 | 0.48 | 0.52 | 0.81 | 0.70 | 0.61 | 0.52 | 0.44 |
| — | — | — | — | — | — | — | — | — | — | — | — | -89.6% | -89.7% | -21.6% | +0.4% | +84.0% | +989.6% | +1299.3% | +1235.0% | +2438.3% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.45 | 0.77 | 1.63 | 2.45 | 2.92 | 3.48 | 1.00 | 3.98 | 4.30 | 5.16 | 4.87 | 4.22 | 2.75 | 3.72 | 2.24 | 2.23 | 1.69 | 2.29 | 3.29 | 4.91 | 3.43 |
| — | -77.9% | +62.3% | -38.6% | -32.2% | -32.5% | -79.4% | -5.7% | +56.2% | +38.8% | +117.6% | +89.7% | +63.0% | +62.2% | -31.9% | -54.7% | -50.7% | -65.2% | -44.7% | -30.9% | -57.3% | |
| Quick Ratio | 2.45 | 0.77 | 1.63 | 2.45 | 2.92 | 3.48 | 1.00 | 3.98 | 4.30 | 5.16 | 4.87 | 4.22 | 2.75 | 3.72 | 2.24 | 1.65 | 1.69 | 2.33 | 3.29 | 4.91 | 3.43 |
| — | -77.9% | +62.3% | -38.6% | -32.2% | -32.5% | -79.4% | -5.7% | +56.2% | +38.8% | +117.6% | +156.0% | +63.0% | +59.3% | -31.9% | -66.4% | -50.7% | -64.5% | -44.7% | -30.9% | -57.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | -7.70 | -10.78 | -6.78 | -9.52 | -12.42 | -13.33 | -14.98 | -50.20 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TCRT stock.
Alaunos Therapeutics, Inc.'s current P/E is -1.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Alaunos Therapeutics, Inc.'s current operating margin is -84500.0%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Alaunos Therapeutics, Inc.'s business trajectory between earnings reports.